L’Oréal: Record First-Half Margins and a Broad-Based Recovery, but 30 Times Earnings Already Prices In the China and Gucci Upside

L’Oréal closed the Kering Beauté acquisition on March 31, 2026. The contractual consideration was €4 billion excluding acquired cash, but provisional purchase-price accounting placed the acquisition price at €4.247 billion. Only €1.406 billion was assigned to identifiable net assets. Goodwill was €2.841 billion, while identifiable intangible assets included the Creed brand at €857 million and €300 million of downpayments related to the future Gucci licence. L’Oréal also obtained 50-year exclusive licences for Bottega Veneta and Balenciaga and the right to operate Gucci beauty under a 50-year licence beginning July 1, 2027, subject to approvals. It will pay royalties to Kering; these are licences, not ownership of the underlying fashion houses.

The strategic case is understandable. Premium fragrance is one of beauty’s stronger categories, Creed supplies an established niche-fragrance platform, and Gucci is a globally recognized name whose beauty sales are small relative to its brand awareness. Management has discussed turning Gucci beauty, currently estimated at approximately €600 million of sales, into a multibillion-euro business, with major new products expected from 2028. The financial case remains unproven. L’Oréal has disclosed slight first-time dilution to the Luxe margin, but not enough acquired profit detail to establish an initial return on the €4.247 billion purchase price. The Gucci transition depends on the expiry and early termination of Coty’s licence, and the new economics include long-term royalties.

The deal also arrived alongside a further €4.213 billion investment that lifted L’Oréal’s stake in Galderma to 20%. The combined deployment pushed net debt including leases to €12.664 billion at June 30, 2026, compared with L’Oréal’s historically cash-rich balance sheet. Credit quality remains strong, with S&P and Moody’s ratings of AA and Aa1 with stable outlooks, but the company’s valuation now depends on management earning a satisfactory return from a much larger pool of recently invested capital.

Ownership is a source of both stability and overhang. The Bettencourt Meyers family held 34.79% at December 31, 2025, and Nestlé held 20.16%. Nestlé’s stake was 20.1% after selling 22.26 million shares back to L’Oréal for €8.9 billion in December 2021. Nestlé’s 2025 financial statements still showed 107.62 million shares and an approximately 20.2% economic interest. Its chief executive described the holding in December 2025 as a financial investment subject to regular review, without announcing an immediate disposal. The latest evidence therefore supports continued ownership, plus a persistent possibility of future supply, rather than an imminent transaction.

Historically, L’Oréal has earned its premium through organic growth, resilient margins and cash conversion. Sales rose from €29.87 billion in 2019 to €44.05 billion in 2025 despite the pandemic and China’s later slowdown. Operating margin increased from 18.6% to 20.2%, and post-capex operating cash flow rose from €5.03 billion to €7.2 billion. The current €387.50 share price represents about 30.5 times 2025 adjusted earnings and 28.7 times 2025 post-capex operating cash flow per share. That is below the most exuberant multiples of the 2021–2023 quality-growth re-rating, but it remains expensive against the French ten-year government bond yield of approximately 3.9% and against slower-growing consumer-staples peers.

The central bull-bear disagreement is therefore precise. Bulls see evidence that L’Oréal can sustain mid-single-digit or better organic growth, use category mix to protect margins, convert Gucci and Creed into another long-duration luxury platform, and keep compounding above the broader beauty market. Bears see a price that already assumes those outcomes, a China recovery that remains narrow, a €4.247 billion acquisition whose initial earnings are undisclosed, and a premium multiple vulnerable to bond yields and any fall in organic growth below 4%.

Qualitatively, this is high-quality compounding growth entering a capital-allocation transition. The operating company has not entered a turnaround: record first-half margins and broad-based growth argue against that label. The transition lies in the balance sheet and in the burden of proof. After spending more than €8 billion on Kering Beauté and the incremental Galderma interest, management must now show that acquired brand equity and licences can produce returns comparable with the company’s historically superior organic reinvestment.

Vertical History and Financial Development

L’Oréal began in Paris in 1909 as the Société Française des Teintures Inoffensives pour Cheveux. Eugène Schueller, a newly trained chemist, developed and patented a synthetic hair dye designed to provide more reliable colour with less damage than many existing preparations, then sold it to Parisian hairdressers. The initial business model already contained three features that survive today: science as a product-development tool, professional recommendation as a distribution channel, and brand-building around visible consumer results.

The early competitors were hair-colour and toiletry manufacturers, salons’ own formulations and established soap and perfumery houses. Most individual firms from that fragmented market have either disappeared or become part of larger groups. The more important continuity is structural: beauty remained a category where formula quality mattered, but consumer trust, fashion and distribution determined which technically adequate product became a global brand.

L’Oréal shares were introduced on the Paris Stock Market on October 8, 1963 and now trade on Euronext Paris’s Compartment A. The available company archive verifies the listing date but does not supply a dependable original offer price, proceeds figure or contemporaneous valuation. Describing the 1963 event as a modern, marketed IPO with known institutional allocations would therefore overstate the historical record. It was the conversion of a successful family-controlled French cosmetics company into a publicly traded company, while the founding family retained substantial control.

France’s political environment shaped the later ownership structure. In 1974, the Bettencourt family entered a cross-shareholding arrangement with Nestlé amid fears of possible nationalisation. The relationship gave L’Oréal a stable international industrial shareholder without surrendering the company to a conventional corporate parent. That arrangement has evolved, including share repurchases from Nestlé in 2014 and 2021, but it still explains why more than half the equity is held by two long-standing blocks.

The company’s development falls into six economically distinct stages.

Scientific haircare and French distribution, 1909 to the early 1960s. The original engine was hair colour, sold through professionals and supported by chemistry. The constraint was reach. Manufacturing and salon relationships could build a national franchise, but global expansion required capital, local distribution and a broader brand portfolio. This period established L’Oréal’s research identity and its habit of working through beauty professionals rather than treating the end consumer as the only decision-maker.

Public ownership and portfolio formation, from 1963 through the 1980s. Listing created a permanent acquisition currency and a route to finance expansion. L’Oréal moved beyond hair colour into mass beauty, prestige cosmetics, skincare and pharmaceuticals. The 1974 Nestlé relationship stabilised control. The enduring result was the architecture that later became the four-division model: brands would be separated by channel, price and customer expectation rather than forced through one undifferentiated sales organisation.

Globalisation under Lindsay Owen-Jones, from 1988 through 2005. The company made one central decision: take locally strong brands and give them global distribution. Acquisitions such as Maybelline in 1996, SoftSheen-Carson, Matrix and Kiehl’s expanded L’Oréal in US mass makeup, textured hair, professional haircare and premium skincare. The group became less French in revenue while preserving central research, brand governance and financial discipline. This stage changed how capital markets saw the company, from a European consumer name into a global growth franchise.

Luxury, channel breadth and portfolio discipline, from 2006 through 2017. L’Oréal bought The Body Shop in 2006 and YSL Beauté in 2008. The first deal showed the limits of the model: retail-store ownership, activist positioning and mid-market natural beauty did not fit as comfortably as formula-led brands distributed through third parties. L’Oréal sold The Body Shop in 2017. YSL Beauté, by contrast, became one of Luxe’s major franchises. CeraVe, acquired in 2017 as part of a transaction valued at $1.3 billion for three skincare brands with approximately $168 million of combined annual sales, became a central example of how the company globalises a pharmacy-led brand.

Digital acceleration and dermatological beauty, from 2018 through 2023. L’Oréal acquired augmented-reality company ModiFace in 2018, increased digital media and e-commerce investment, and benefited when pandemic restrictions pushed consumers toward online beauty discovery. E-commerce reached 28.9% of sales in 2021. Dermatological Beauty, built around La Roche-Posay, CeraVe, Vichy and SkinCeuticals, grew far faster than the rest of the group as consumers sought clinically positioned skincare. Sales in the division grew 28.4% like-for-like in 2023. L’Oréal also completed the $2.525 billion Aesop acquisition in 2023, then its largest purchase.

Large-scale capital deployment and licensed luxury, from 2024 onward. The current stage expands the company’s model from acquiring beauty brands into operating fashion-house beauty licences at unprecedented scale. Kering Beauté and the 20% Galderma stake together committed more than €8 billion in 2026. L’Oréal remains operationally healthy, but its balance sheet now carries more debt, goodwill and equity-accounted assets. This stage will be judged by incremental returns, not by the prestige of the acquired names.

Several capital nodes continue to shape the equity story.

The CeraVe acquisition was initially expensive against acquired sales, but L’Oréal placed the brand into pharmacies, drugstores, dermatology recommendation networks and e-commerce across multiple countries. Its subsequent scale helped Dermatological Beauty become the group’s highest-margin division. That success supports management’s claim that L’Oréal can pay for under-distributed brand equity and create value through distribution. It also raises the market’s expectations for every later acquisition.

The Body Shop is the counterexample. L’Oréal can struggle when the acquired business depends on owned stores, a distinctive corporate culture or a proposition that cannot be amplified mainly through research, media and existing retail partners. The lesson for Kering Beauté is that brand recognition by itself is insufficient. The acquired assets must fit the group’s product-development and distribution machine.

The December 2021 Nestlé repurchase was one of the largest capital actions in company history. L’Oréal bought 22.26 million shares at €400 each and cancelled them, paying about €8.9 billion. It reduced Nestlé’s stake from about 23.3% to 20.1% and increased every remaining holder’s economic claim. It was struck close to a period of unusually high valuation, however. The repurchase improved ownership structure more clearly than it created an obvious financial bargain.

Aesop showed that L’Oréal was willing to pay a high initial multiple for scarcity, direct-to-consumer identity and a differentiated store experience. Purchase-price accounting recorded only €13.1 million of operating profit from €557.5 million of full-year-equivalent sales disclosed around the acquisition period, although those figures include timing and acquisition effects and should not be read as mature economics. The brand has since grown double digits, but the original return cannot yet be evaluated over a full cycle.

Kering Beauté is larger and more complicated. The consideration comprises Creed ownership, long-dated licences and a deferred Gucci operating opportunity. The €2.841 billion of goodwill equals about two-thirds of the provisional purchase price. The Gucci licence starts on July 1, 2027 after early termination of Coty’s arrangement; new major products are expected later. The acquisition therefore contains a gap between cash payment and full earnings potential. That raises execution and time-value risk even if Gucci eventually becomes a large franchise.

The financial record illustrates why shareholders have historically accepted a premium valuation.

The underlying figures come from company filings and annual-results releases.

Sales compounded by about 6.7% annually from 2019 through 2025. Part of that came from acquisitions, but the larger drivers were organic volume and value growth, geographic expansion, category mix and pricing. Reported growth frequently differed from like-for-like growth because more than half of sales come from outside the eurozone. Currency reduced reported growth by 5.0 percentage points in 2023, 3.6 points in 2025 and 2.8 points in the first half of 2026. Investors should therefore read brand momentum off like-for-like growth and treat earnings translation separately.

Operating margin rose by 160 basis points between 2019 and 2025 despite pandemic disruption, inflation and the Chinese travel-retail correction. Scale, product mix, pricing and SG&A efficiency created the improvement. Gross margin remained in the mid-70s because cosmetic ingredients are generally a modest portion of the retail price; brand investment, packaging, distribution, retailer economics and product development matter more. That does not make margins automatic. Fashion changes, weak launches or excess inventory can force promotional spending and destroy gross-margin quality.

Cash conversion has been solid. From 2021 through 2025, cash from operations before capex totalled about €37.6 billion against approximately €31.1 billion of adjusted net profit, a ratio of roughly 1.21 times. Post-capex operating cash flow totalled about €30.5 billion, or about 0.98 times adjusted profit. Working capital caused the largest annual fluctuations, including a €1.01 billion increase in requirements in 2022, but there is no persistent pattern of earnings failing to become cash.

Capital expenditure usually runs at 3–4% of sales. It supports factories, distribution, information systems, laboratories and digital infrastructure rather than a commodity-scale capacity race. L’Oréal does not disclose a maintenance-versus-growth split. Based on the maturity of the manufacturing footprint and the continued expansion of laboratories, digital systems and emerging-market capacity, this report estimates that 60–70% of normal capex is maintenance or recurring modernisation and 30–40% is growth-oriented. The valuation uses total capex, making it more conservative than relying on the estimated maintenance portion alone.

The balance sheet changed sharply in 2026. At June 30, assets included €17.67 billion of goodwill, €6.33 billion of other intangible assets and €8.81 billion of equity-accounted investments, principally Galderma. Cash was €4.05 billion, while borrowings and lease obligations were substantially higher. Net debt including leases was €12.66 billion. These figures do not indicate financial distress: annual operating profit exceeds €9 billion on a run-rate basis, and credit ratings remain high. They do reduce capacity for another acquisition of similar size without further leverage or asset recycling.

The company’s return on tangible operating capital is exceptionally high because formulas and manufacturing assets require far less capital than the economic value created by brands. Advertising is expensed rather than capitalised, which can overstate conventional return-on-invested-capital calculations by omitting a large internally built brand asset. Acquired goodwill has the opposite effect by placing purchased brand value on the balance sheet. Using a broad invested-capital base that includes acquisition goodwill and 2026 debt, this report estimates current after-tax operating returns in the mid-teens. That remains above a reasonable cost of capital, but it is lower than the returns produced by established internally developed brands. The return from Kering Beauté cannot yet be isolated.

The share-price record over the last decade follows the interaction of earnings and the discount rate. From the mid-2010s through 2021, improving organic growth, low bond yields and enthusiasm for dependable quality growth produced both earnings gains and multiple expansion. The pandemic caused a short fall, followed by a rapid recovery as e-commerce, skincare and fragrance demand accelerated. In 2022 and 2023, earnings growth and Dermatological Beauty offset higher interest rates, taking the share price toward record levels.

The narrative weakened during 2024 and early 2025. North Asia contracted, Chinese travel retail destocked and Luxe slowed. L’Oréal’s fourth-quarter 2024 like-for-like growth was only 2.5%, compared with 6.9% a year earlier. The market began treating the company less as an uninterrupted double-digit grower and more as a quality franchise with a cyclical Chinese exposure.

Momentum then improved. Third-quarter 2025 growth was 4.2% like-for-like, fourth-quarter growth reached 6.0%, first-quarter 2026 adjusted growth was 6.7%, and second-quarter adjusted growth was 6.3%. The share price still fell after the February 2026 annual results because the market wanted a stronger North Asia recovery and worried about acquisition dilution; it rose 2.74% on July 30 after H1 margins and adjusted growth exceeded expectations. The 2026 closing-price range through August 4 was €338.85–€405.80.

At €387.50, the stock trades at about 30.5 times 2025 adjusted EPS. Third-party historical series place the current trailing multiple below L’Oréal’s three-, five- and ten-year averages, although those comparisons are sensitive to earnings definitions and pandemic-distorted periods. A more reliable reading is that the present multiple is below the 2021–2023 peak, close to the middle of the post-2020 range and above the pre-pandemic consumer-staples norm. The valuation centre shifted upward because L’Oréal added faster-growing dermatological beauty and e-commerce exposure, then remained elevated because investors continued to value earnings resilience. Higher European bond yields now make the same multiple more demanding.

Business Model, Industry and Competitive Position

L’Oréal reports four operating divisions. Each has different customers, channels, growth rates and competitive economics, which makes them distinct businesses, not accounting segments.

We calculate sales mix and growth contribution from company disclosures.

Professional Products serves salons, stylists and premium haircare consumers through brands including Kérastase, L’Oréal Professionnel, Redken and Matrix. The customer proposition is technical performance reinforced by professional recommendation. Distribution has broadened from salons into selective retail and e-commerce, but the stylist remains an important credibility channel. Premiumisation in haircare and expansion into countries with low salon-product penetration support growth.

Consumer Products is the volume and scale engine. L’Oréal Paris, Garnier, Maybelline New York and NYX Professional Makeup sell through mass retail, drugstores and online channels. The division provides manufacturing scale, retailer bargaining power and access to a broad consumer base. It still matters despite the lower growth rate: it generates more than one-third of sales and had a 22.7% first-half operating margin. Haircare and makeup accelerated in late 2025, but the division faces the greatest pressure from private labels, low-cost local brands and rapid trend turnover.

L’Oréal Luxe sells Lancôme, Yves Saint Laurent Beauté, Giorgio Armani Beauty, Prada Beauty, Aesop and other prestige brands through department stores, specialist retailers, travel retail, boutiques and e-commerce. The economics combine owned brands with long-term licences from fashion houses. The product gross margin can be high, but retail concessions, samples, prestige packaging, celebrity campaigns and royalties absorb part of the benefit. The Kering assets sit here. Luxe is central to perception because it represents one-third of group revenue and carries disproportionate exposure to China and travel retail.

Dermatological Beauty includes La Roche-Posay, CeraVe, Vichy, SkinCeuticals and other clinically positioned skincare. It sells through dermatologists, pharmacies, drugstores, medical-aesthetic channels and e-commerce. Its 28.4% operating margin was the highest of the divisions in H1 2026. The category benefits from repeat use, scientific claims, ageing populations, concern about sensitive skin and the blurring of cosmetics with health and wellness. The main risk is that “dermatological” becomes a marketing label adopted by every competitor, weakening differentiation unless claims and professional recommendation remain credible.

The business machine begins with product development and ends with repeated purchase. Research identifies a need, such as scalp health, skin barrier repair or long-wear makeup. Formulation and testing convert the need into a claim, and brand teams then set the price, packaging and emotional identity. Media spending creates awareness, while retailer, salon, pharmacy and digital relationships secure availability. Consumer data and sell-through results then determine where to scale the launch.

Raw ingredients, packaging, manufacturing and freight are primarily variable costs. Research laboratories, management, information systems, manufacturing overhead, sales forces and parts of the retail network are fixed or semi-fixed. Advertising and promotion is economically discretionary in the short term but difficult to cut without weakening future demand. This is why L’Oréal has operating leverage but does not behave like a software company. A sales decline would reduce factory utilisation and retailer leverage, while management would probably continue supporting major brands, causing profit to fall faster than revenue.

Scale provides purchasing and manufacturing benefits, but the larger advantage is spreading research, regulatory work, digital content and retailer relationships over €44 billion of annual sales. A small brand must negotiate separately with retailers, influencers and regulators in each market. L’Oréal can reuse the infrastructure while keeping brand identities distinct.

The company’s moat rests on four durable capabilities.

The first is portfolio-and-channel architecture. L’Oréal can serve a mass shopper, a salon client, a luxury-fragrance buyer and a dermatologist-referred skincare user without forcing them into one brand. This reduces dependence on any single category and provides internal routes for innovation. A consumer may enter through Garnier and later purchase Lancôme, CeraVe or Kérastase, even though L’Oréal does not need to market that journey as a corporate ecosystem.

The second is distribution density. The company has relationships across mass retailers, pharmacies, salons, department stores, airport shops and online platforms. This does not prevent a digitally native competitor from gaining attention, but it raises the cost of turning attention into broad physical availability. CeraVe’s expansion illustrates how distribution can create more value than the acquired formula alone.

The third is sustained reinvestment. H1 2026 advertising and promotion equalled 32.6% of sales, and research spending equalled 2.9%. A single campaign is a marketing asset rather than a moat. Funding thousands of launches, abandoning weak ones and supporting winners through multiple years is a structural advantage.

The fourth is acquisition and licensing capability. L’Oréal can buy brands before their international potential is exhausted and place them into the appropriate division. Maybelline, Kiehl’s, CeraVe and YSL Beauté support that record. Body Shop shows that the capability has boundaries, while Aesop and Kering Beauté remain tests still in progress.

Technology is supportive; it is not independently decisive. ModiFace, virtual try-on, digital media targeting and artificial intelligence can improve conversion and product development. Rivals and retailers can access similar tools. The moat lies in applying technology to a large proprietary stream of product, consumer and sell-through information, not in exclusive control of a foundational technology.

Switching costs are low at the individual-product level. A consumer can replace a lipstick or shampoo easily. Habit, skin compatibility, fragrance preference and professional recommendation create behavioural stickiness, but they do not create contractual captivity. L’Oréal must continually renew the moat through product efficacy and cultural relevance.

Governance combines professional management with concentrated ownership. Nicolas Hieronimus has served as chief executive since May 2021 after joining L’Oréal in 1987 and running major geographic and divisional businesses, including Professional Products. Jean-Paul Agon, chief executive from 2006 to 2021, remains chairman. The succession preserved operating continuity while separating the chair and chief-executive positions.

The Bettencourt Meyers family’s 34.79% stake aligns it with long-duration value creation and discourages leverage-driven financial engineering. Nestlé’s 20.16% stake adds another stable block, although its status as a financial investment creates eventual-sale uncertainty. Together, the two holders controlled 54.95% of the equity at year-end 2025. Free float was approximately 45.05%. Minority shareholders therefore benefit from stability but have limited influence over control.

L’Oréal does not have a US-style dual-class structure. Family influence comes from economic ownership and board representation rather than super-voting founder stock. The principal governance question is capital allocation. The record includes value-creating acquisitions, a failed strategic fit at The Body Shop, an expensive 2021 buyback and unusually large 2026 commitments. Management credibility is high in operations; the return from the latest capital deployment remains to be earned.

No evidence from the reviewed filings indicates a systemic accounting fraud or repeated auditor dispute. H1 2026 included €169 million of product-liability litigation charges, €50 million of restructuring charges, €42 million of acquisition-related costs and a €188 million exceptional French tax surcharge. These reduced reported net profit relative to adjusted profit and should not be treated as recurring operating expenses, although product litigation is a genuine external risk rather than an accounting adjustment with no economic cost.

The broader beauty market remains structurally attractive but increasingly competitive. McKinsey forecasts approximately 5% annual global growth through 2030, reaching about $590 billion, equivalent to roughly €512 billion using the August 4, 2026 ECB rate of €1 to $1.1515. Emerging markets, particularly Latin America and Southeast and Central Asia, are expected to grow faster than mature Europe.

Growth comes from several independent sources: population and income growth in emerging markets; higher beauty participation among men and older consumers; premiumisation; new routines around scalp care, sun protection and skin barriers; social-media-led product discovery; and higher fragrance penetration. Pricing contributes, but value-conscious consumers have become more selective and promotional intensity has risen.

The profit pool concentrates in differentiated brands, scarce licences and effective distribution. Ingredient suppliers usually capture a smaller share unless they own patented actives. Retailers and digital platforms retain bargaining power because they control traffic, but desirable brands can negotiate better shelf space and terms. Fashion houses can capture royalties without operating the beauty supply chain. That explains the appeal of licensing and its limitation: L’Oréal gains a long operating runway while sharing the economics with the licensor.

Entry barriers are low for launching a brand and high for sustaining one at global scale. Contract manufacturers, social platforms and online marketplaces allow founders to enter quickly. Customer-acquisition costs, retailer working capital, product compliance and repeated innovation make profitable scale much harder. L’Oréal faces more new brands than it did twenty years ago, but it also has more acquisition candidates.

Two demand debates should remain separate.

China and North Asia are cyclical and geographic. Property stress, lower confidence, travel-retail inventory reductions and stronger local brands weakened Chinese beauty. Prestige beauty is now improving faster than high-ticket luxury goods because a premium serum or fragrance is an attainable luxury purchase. That supports L’Oréal Luxe and Dermatological Beauty. A durable recovery still requires broader consumer demand, less discounting and consistent travel-retail sell-through.

The global category shift toward dermatological products, premium haircare and fragrance is structural. It appears across regions and reflects routines, efficacy claims and affordable indulgence. H1 2026 confirms the difference: Dermatological Beauty and Professional Products grew about two and a half times as fast as Consumer Products and carried equal or higher margins. A renewed Chinese cycle would add to that shift, but the shift does not depend entirely on China.

Beauty is partly defensive and partly cyclical. Low-ticket shampoo, skincare and makeup are repeat purchases with relatively low absolute price points. Premium fragrance, travel retail and high-end skincare respond more strongly to confidence, tourism and gifting. L’Oréal’s mix is therefore less defensive than household essentials but more resilient than fashion, jewellery or leather goods.

Regulation is a continuous operating cost, not an existential licence. Cosmetics companies must substantiate claims, comply with ingredient restrictions, monitor adverse reactions and meet packaging and environmental rules. The EU is generally tightening chemical, sustainability and product-disclosure requirements. Large global companies can absorb testing and reformulation costs better than small competitors, making regulation a modest scale advantage. It can still create recalls, litigation and reputational harm.

Geopolitical and tariff risks enter through currency, logistics, ingredients and consumer sentiment. H1 2026 currency translation reduced sales growth by 2.8 percentage points. The Middle East conflict reduced second-quarter revenue by an estimated €30 million, while US tariffs had an approximately 20-basis-point margin effect according to management reporting. Neither is currently large relative to group profit, but persistent trade fragmentation would raise costs and complicate global launches.

The peer landscape contains several direct but incomplete comparables. Estée Lauder is closest in prestige cosmetics, Beiersdorf in skincare and dermatological products, Shiseido in Asian prestige beauty, and Procter & Gamble in mass beauty and global consumer distribution. Coty and Puig are relevant to fragrance licensing; LVMH and Kering matter because luxury groups own brand equity that can be operated internally or licensed.

The peer metrics use each company’s own definitions and reporting periods, so they indicate relative direction rather than perfect accounting comparability.

Estée Lauder became a concentrated prestige and travel-retail company. Customers choose La Mer, Estée Lauder, Jo Malone, Le Labo and Tom Ford for luxury positioning, fragrance identity and department-store presence. That concentration produced strong economics when Asian travel retail expanded and severe operating deleverage when the channel destocked. Fiscal third-quarter 2026 organic sales grew 2%, fragrance grew double digits and mainland China improved, but management’s preliminary fiscal 2027 operating-margin goal of 12.5–13.0% remains far below L’Oréal’s 21% level. Estée Lauder offers greater turnaround upside and greater execution risk.

Beiersdorf became a focused skincare company with NIVEA as its global mass franchise and Eucerin and Aquaphor as its derma engine. Customers choose it for recognised moisturising and skin-health products rather than breadth across makeup, salon haircare and luxury fragrance. H1 2026 organic sales fell 3.5% and Consumer sales fell 4.0% because NIVEA weakened, while derma continued to outperform. Its 15.5% adjusted margin and strong balance sheet provide resilience, but the group has less category diversification and less luxury optionality than L’Oréal.

Shiseido became an Asian prestige specialist with valuable skincare brands and an unusually heavy dependence on Japan, China and travel retail. Its technical skincare heritage remains credible, but repeated restructuring and uneven international acquisitions have reduced investor confidence. Q1 2026 like-for-like sales fell 3%, core operating margin was 5.6%, and free cash flow was negative ¥7.1 billion. Cost savings lifted profit, but growth quality remained inferior to L’Oréal’s.

Procter & Gamble is a scale benchmark rather than a pure beauty peer. Its Beauty segment grew 4% organically in fiscal 2026, with haircare and personal care offsetting flat skincare. P&G has stronger household penetration and supply-chain scale, but beauty competes internally for capital with laundry, baby care, grooming and health products. L’Oréal offers purer exposure to beauty category growth and much more luxury and dermatological breadth.

Puig and Coty are the most useful licensing comparisons. Both are heavily exposed to prestige fragrance and fashion-house licences. They can grow quickly during a fragrance cycle but face licence-renewal risk and higher category concentration. Puig’s H1 2026 like-for-like revenue growth was 4.4%, below L’Oréal’s adjusted rate, while the industry was beginning to normalise after a strong post-pandemic fragrance cycle.

L’Oréal’s ecological niche is the global beauty consolidator with the widest credible channel range. It takes profit pools from small brands that cannot fund global distribution, from retailers’ private labels that lack aspiration, and from fashion houses that prefer royalties to operating complexity. Its greatest long-term threat is a combination of local digital brands, retailers controlling consumer data and fashion groups internalising beauty operations. Its position usually strengthens during regulatory tightening or a marketing-cost increase because smaller entrants suffer more. It weakens when cultural relevance moves faster than the company’s brand-development process or when it overpays for growth.

Current Fundamentals and Capital-Market Narrative

The latest four quarterly trading periods show a business that decelerated, stabilised and then reaccelerated.

Third-quarter 2025 sales were €10.33 billion, up 4.2% like-for-like and 0.5% reported, bringing nine-month revenue to €32.80 billion. Nine-month like-for-like growth was 3.4%, constant-currency growth was 4.0%, and currency reduced reported growth by 2.8 percentage points. This was still a weak point in the recent cycle, shaped by North Asia and a slower Luxe division.

Fourth-quarter 2025 sales were €11.245 billion, up 6.0% like-for-like and 1.5% reported. Professional Products grew 7.6%, Consumer Products 4.8%, Luxe 4.5% and Dermatological Beauty 11.5%. North Asia returned to 0.6% like-for-like growth after contraction, while North America grew 8.6%. The quarter established the first credible sign that the slowdown was ending.

First-quarter 2026 sales reached €12.152 billion. Unadjusted like-for-like growth was 7.6%, but adjusted growth was 6.7% after accounting for information-system shipment phasing. Professional Products grew 13.1% on the adjusted basis and Dermatological Beauty 10.2%. The quality of the result was better than a China-only rebound because every division grew, although phasing required investors to avoid extrapolating the unadjusted number.

Second-quarter sales were €11.624 billion, up 6.0% like-for-like, 6.3% adjusted like-for-like and 8.2% reported. The adjusted result exceeded market expectations of approximately 5.7%. Professional Products and Dermatological Beauty maintained double-digit momentum; Luxe and Consumer Products grew in the mid-single digits. Creed, Bottega Veneta and Balenciaga were consolidated for the quarter, lifting scope growth.

The apparent reversal between reported and organic growth illustrates the currency discipline needed for the stock. In Q2, reported growth exceeded adjusted organic growth because acquisition scope contributed and the currency drag eased from the level carried earlier in the year. For the half year as a whole, currency remained a 2.8-point drag. An investor valuing L’Oréal in euros receives translated earnings, even when local-market brand performance is stronger.

Regional breadth improved. Europe grew 6.1% adjusted in H1, North America 6.7%, North Asia 4.6%, SAPMENA–SSA 13.8% and Latin America 5.2%. North America’s adjusted growth was lower than the reported like-for-like measure because IT phasing boosted shipments, while Latin America’s adjusted rate was higher than the unadjusted measure after correcting prior-year effects. Emerging markets remained the fastest structural opportunity, but they carry currency volatility.

First-half gross profit was €17.777 billion. Advertising and promotion increased by 70 basis points to 32.6% of sales, while SG&A fell by 70 basis points to 18.0%. Research spending remained 2.9%. This is healthy operating leverage: administrative efficiency funded consumer investment, while gross margin held. It would become less healthy if future margin growth depended on cutting media or research.

Division economics show where the incremental quality comes from. Dermatological Beauty’s 28.4% margin is 710 basis points above the 21.3% group operating margin, and Professional Products expanded its margin by 90 basis points. Consumer Products expanded by 20 basis points. Luxe fell by 20 basis points to 22.1%, reflecting initial Kering Beauté dilution. The group can therefore grow profit faster than sales if derma and professional remain the leading contributors. A recovery led mainly by lower-margin or heavily licensed products would provide less leverage.

Cash flow was seasonally weaker than earnings but not alarming. Gross cash flow reached €4.791 billion. Working capital consumed €952 million and capex consumed €716 million, leaving €3.123 billion of post-capex operating cash flow. Acquisition payments were €4.030 billion, and financial investments were €4.226 billion, primarily Galderma. Dividends consumed €3.926 billion. Debt issuance and existing liquidity funded the difference.

Inventory stood at €4.935 billion, about 10.4% of annualised first-half sales, and receivables were €6.634 billion. Neither figure is abnormal for the scale and channel mix, but both warrant attention after acquisitions and information-system changes. Luxury and travel-retail inventory can become a hidden source of discounting if sell-through falls below shipments.

Management continues to expect another year of sales and profit growth despite geopolitical, tariff and currency pressures. It has not issued precise organic-sales or EPS guidance in the style of a US company. Commentary on Kering Beauté indicated slight EPS dilution in 2026 and limited growth contribution in 2027 while L’Oréal invests in the brands. That places more of the deal’s financial payoff in 2028 and later.

The market is currently trading four variables.

The first is proof that L’Oréal has returned to at least its mid-single-digit organic-growth algorithm. The acceleration from 3.4% over the first nine months of 2025 to 6.0% in Q4 and about 6.5% adjusted in H1 2026 supports the case. The market will punish a return below 4% because the current multiple offers little room for mature-staples growth.

The second is China’s direction. North Asia’s 4.6% adjusted H1 growth and the second consecutive half-year of improvement support an inflection. The concentration in premium fragrance, professional and dermatological products leaves the breadth uncertain. Evidence of positive Chinese mass skincare, sustainable travel-retail sell-through and reduced promotional intensity would convert the current selective recovery into a stronger thesis.

The third is category mix. Dermatological Beauty and Professional Products are faster and at least as profitable as the group. Their sustained double-digit growth supports a higher long-term margin and multiple. Consumer Products remains essential for scale, but its 4.3% adjusted growth is closer to the broader beauty market.

The fourth is M&A. Investors are assigning some option value to Gucci, Creed and Galderma before the return is visible. That is reasonable for a company with L’Oréal’s integration record, but it is also the most speculative part of the current valuation.

The bulls’ evidence is substantial. L’Oréal is growing faster than the approximately 5% projected global beauty market, every division is positive, two high-margin divisions are growing above 10%, North Asia has improved, and first-half operating margin reached a record while brand spending increased.

The bears’ evidence is equally specific. Adjusted EPS grew only 4.8%, below adjusted sales growth, because financing, acquisition dilution and non-operating effects matter. The China recovery is selective. Luxe growth is only mid-single digit and its margin has begun to absorb the Kering assets. Net debt has risen to €12.7 billion. At approximately 30 times trailing adjusted earnings, the share price assumes that those issues are temporary rather than structural.

Analyst expectations appear to have moved modestly upward after H1, without a wholesale re-rating. A market-data consensus cited around the result placed 2026 EPS near €13.70, compared with €12.71 in 2025, although providers differ in the treatment of exceptional items and ADR ratios. The share-price response after the H1 release was positive but restrained, consistent with a result that reduced near-term fears without resolving long-term acquisition returns.

Valuation, Risks and Catalysts

The valuation begins with cash passthrough.

Over 2021–2025, operating cash flow before capex was approximately 1.21 times adjusted net income. After all capex, the ratio was approximately 0.98 times. The lower post-capex figure reflects ordinary investment, not chronic working-capital leakage. Post-capex cash flow exceeded adjusted income in 2021 and 2025 and fell just short in 2023 and 2024, while 2022 was the weakest year because working capital consumed about €1.01 billion.

L’Oréal does not split maintenance and growth capex. This report estimates a 60–70% maintenance share, but uses total capex when defining owner earnings. That avoids assigning uncertain growth value to factories, systems or laboratories.

2025 post-capex operating cash flow of approximately €7.2 billion equalled about €13.49 per share using the year-end share count. At €387.50, the resulting owner-earnings multiple is about 28.7 times and the owner-earnings yield is approximately 3.5%. The headline adjusted P/E using €12.71 EPS is about 30.5 times. The difference is only about 6%, well below the 30% threshold that would require abandoning accounting earnings as a useful valuation measure. Both earnings and cash flow therefore support a similar conclusion: L’Oréal is priced for durable growth, not for stagnation.

Historical valuation provides some comfort but no bargain signal. The current multiple is below several post-2020 averages and below peak quality-growth valuations, but the comparison period included exceptionally low bond yields. France’s ten-year government-bond yield was approximately 3.9% on August 4, 2026, slightly above L’Oréal’s owner-earnings yield. Investors receive dividend growth and earnings growth on top of that yield, but they also carry equity, execution and multiple risk.

Peer valuation supports a premium over troubled beauty companies but does not establish intrinsic value. Estée Lauder and Shiseido have lower profitability and are executing turnarounds. Beiersdorf has a lower margin and a contracting mass franchise. P&G offers greater diversification and usually trades at a lower multiple because its growth runway is slower. L’Oréal deserves a relative premium for breadth, margin and execution. A 30-times multiple still requires organic growth of roughly 5–7% and stable margins. The premium would be difficult to defend if the growth gap narrowed.

Absolute valuation uses owner earnings, adjusted EPS and an exit-multiple cross-check. The present value ranges assume a 7.5–8.0% cost of equity, broadly consistent with a low-beta consumer franchise but above the French government yield. They do not assign a separate speculative value to Galderma beyond its carrying and observable market value.

The expected returns include dividends and assume a three-to-five-year holding period. They are valuation-scenario analysis within a research framework, not investment advice.

The conservative range assumes that China improves only modestly, Consumer Products tracks the market, Kering Beauté earns a return below L’Oréal’s historical average, and valuation normalises toward high-quality staples rather than premium growth. The resulting €315–€340 fair value is below the current price.

The base range assumes adjusted organic growth settles around 5–6%, operating margin remains above 20%, Dermatological Beauty grows faster than the group, and Gucci begins contributing without a severe launch-cost overrun. It does not require another 2021-style multiple expansion. The €380–€410 range places the current share price near fair value.

The optimistic range requires China to become a durable growth contributor, Gucci beauty to move convincingly toward the multibillion-euro ambition, and group organic growth to remain above the global market. Even under those assumptions, a valuation much above €500 would depend on preserving a near-30-times terminal multiple.

The expectation gap at the next results release will centre on adjusted rather than raw like-for-like growth. The market will also watch North Asia’s adjusted growth, US momentum, Luxe margin dilution, and whether management provides quantified Kering sales or profit information. The next scheduled release is sales for the nine months ended September 30, 2026, after market on October 22, followed by a conference call.

The market may be underestimating the durability of Professional Products. Premium haircare has grown through salons, selective retail and e-commerce, reducing dependence on salon traffic alone. It may also be underestimating the time required for Gucci. The licence starts in July 2027 and major product renovation is expected around 2028, leaving acquisition costs ahead of the full revenue opportunity.

The margin-of-safety review produces a stricter conclusion than the peer comparison.

Current price versus conservative value: €387.50 is about 14–23% above the €315–€340 conservative fair-value range. The margin of safety is zero.

Most fragile assumption: the base-case terminal multiple. Reducing the 27-times midpoint by 30% to 18.9 times lowers the base valuation from around €395 to approximately €265–€285, even without a collapse in earnings.

Flat-earnings test: if adjusted earnings remain flat for three years and the multiple is unchanged, the return would consist mainly of the approximately 1.9% dividend yield. That is below the approximately 3.9% French ten-year government-bond yield. There is no margin of safety at this buy price.

Good-company-versus-price test: L’Oréal is a good company at a price that is fair only if growth remains healthy. Waiting for a lower entry point is financially rational for a new investor because the existing yield does not compensate for a multi-year earnings pause.

Margin-of-safety sufficiency verdict: none.

Five risks have a credible path to permanent capital loss.

China’s recovery may prove narrow. Probability is medium and impact high. If selective beauty and premium fragrance continue growing while mass skincare, travel retail and consumer confidence remain weak, North Asia may settle near zero to low-single-digit growth. Luxe would lose operating leverage, the group growth rate could fall below 4%, and the market could reclassify L’Oréal from a structural grower to a defensive staple. The observable indicators are adjusted North Asia growth, Chinese sell-through rather than shipments, travel-retail inventory and Consumer Products growth in the region.

The Kering transaction may earn less than L’Oréal’s cost of capital. Probability is medium and impact medium to high. Goodwill of €2.841 billion, royalties and the delay before Gucci’s full launch create a high hurdle. If Gucci remains near its current scale, Creed loses niche-fragrance momentum or launch spending rises, Luxe margin could remain diluted through 2028–2029. The transmission path runs from weak acquired profit to lower ROIC, slower EPS growth and a reduced acquisition premium.

Valuation compression is a medium-to-high-probability, high-impact risk. At about 30 times trailing adjusted earnings, a reduction to 22 times with EPS held at €13–€14 would imply a share price near €286–€308. No business collapse is required. Higher bond yields, a style rotation or repeated 3–4% organic growth could cause it. The observable indicators are the French ten-year yield, L’Oréal’s forward P/E and its organic-growth premium over the market.

Capital allocation may remain aggressive after the balance-sheet shift. Probability is low to medium and impact medium. Net debt including leases of €12.7 billion is manageable, but another major acquisition before Kering and Galderma returns become visible would raise the risk of leverage, goodwill impairment or reduced buyback flexibility. Net debt relative to operating profit and additional investment in Galderma are the key measures.

A Nestlé sell-down could create a technical and governance overhang. Probability is low to medium; business impact is low, but share-price impact could be medium. A marketed sale of even part of the 20.16% stake would exceed normal trading liquidity and could temporarily compress the multiple. A sale to a strategic buyer could alter governance. The latest dated evidence shows no announced disposal, so the risk should be monitored rather than assumed.

Other risks include product-liability litigation, ingredient restrictions, adverse currency translation, cyber and information-system disruption, local digital competitors and prolonged Middle East or trade tensions. None currently outweighs the five principal loss paths.

Positive catalysts over the next year include adjusted like-for-like growth remaining above 6%, North Asia sustaining mid-single-digit growth without shipment benefits, Dermatological Beauty maintaining double-digit growth, quantified Creed profitability, a manageable Gucci transition budget and lower European bond yields. A material buyback is unlikely to be the central catalyst while leverage is elevated.

Negative catalysts include adjusted group growth below 4%, North Asia returning to contraction, Luxe margin falling below 21%, Consumer Products losing volume, Kering-related EPS dilution extending beyond 2027, another large acquisition or evidence that Nestlé is preparing a substantial placement.

The following dashboard turns those catalysts into observable thresholds.

The group-growth measure should always be adjusted for IT phasing and separated from scope and currency. North Asia needs two or more additional periods of positive adjusted growth before the recovery can be called broad and durable. Dermatological Beauty below 6% would matter because the current valuation assumes it remains a structural growth engine. A falling advertising ratio would only be positive if sales and brand share remain strong; otherwise, it could indicate short-term margin management.

Net debt is less important in isolation than the return on the assets that created it. Investors should compare Kering-related operating profit with the €4.247 billion acquisition price and monitor Galderma’s earnings contribution against the €8.81 billion carrying amount of equity-accounted investments.

Cross-Synthesis, Research Conclusion, Sources and Uncertainties

L’Oréal’s proven capability is institutional rather than product-specific. It has survived changes from salon hair colour to mass makeup, prestige fragrance, e-commerce and dermatological skincare because it repeatedly reorganised around where consumers discovered and trusted beauty products. The names and channels changed; the method remained science, segmentation, marketing and distribution.

Past success came partly from favourable eras. Rising emerging-market incomes, department-store expansion, China’s luxury boom, digital media and the post-pandemic fragrance cycle all helped. Those tailwinds do not explain why L’Oréal’s operating margin rose from 18.6% in 2019 to 20.2% in 2025 while several peers lost profitability. Portfolio breadth, brand reinvestment and execution made the difference.

The capabilities remain present. First-half 2026 sales growth was broad, advertising increased as a percentage of sales, and operating margin still reached a record. The two fastest divisions were also attractive economically. That combination is stronger evidence of continuing business quality than a rising share price or a management promise.

The horizontal comparison makes the advantage clearer. Estée Lauder offers prestige-brand strength but is rebuilding after channel concentration. Beiersdorf offers skincare credibility but has a weaker NIVEA cycle and less category breadth. Shiseido has scientific heritage but much lower group profitability. P&G has greater consumer scale but less exposure to luxury and derma. L’Oréal’s advantage is that it can move capital and talent among mass, luxury, professional and medical-adjacent beauty without abandoning its category focus.

Its weakness is the price attached to that advantage. The current valuation rewards proven history and spends part of the future in advance. A 30-times earnings multiple can survive a short regional slowdown; it is much less forgiving of a structural decline in organic growth or a major acquisition that earns single-digit returns.

The market is most likely misjudging two things in opposite directions. It may still view China too simplistically. H1 2026 provides evidence of an inflection, but the improvement is category-specific and partly compared with a weak base. It may also be treating Kering Beauté as an immediately scalable package. Creed can contribute now, but Gucci is a 2027–2028 development story with royalty and transition economics that differ from owning a brand outright.

Over the next year, adjusted organic growth and North Asia breadth matter most. Over three years, Gucci launch execution, Luxe margin and post-acquisition ROIC become decisive. Over five years, the issue is whether L’Oréal can maintain its historical growth premium as beauty discovery fragments across social commerce, local brands and medical-aesthetic channels.

The company becomes a better investment under three conditions: the share price falls enough to provide a cash-yield and multiple margin of safety; Kering disclosures establish an attractive return path; or organic growth rises without requiring higher working capital, promotion or leverage. The thesis should be overturned if Dermatological Beauty loses its growth premium, group adjusted organic growth remains below 4% for several periods, or the company continues making large acquisitions before the current ones earn their cost of capital.

[Core bull reasons]

• H1 2026 adjusted like-for-like growth reached 6.5%, above the projected long-term global beauty-market growth rate, with every division and region positive.
• Professional Products and Dermatological Beauty grew 11.6% and 10.6% respectively and together generated about 56% of reported incremental sales despite representing about 30% of revenue.
• Operating margin reached 21.3% while advertising and promotion rose to 32.6% of sales, indicating that margin expansion did not depend on withdrawing brand support.
• North Asia achieved a second consecutive half-year of positive growth, with China gaining share in premium fragrance, dermatological beauty and professional products.
• Cash from operations exceeded adjusted net income over the last five years before capex, and post-capex conversion was approximately complete.

[Core bear reasons]

• At €387.50, L’Oréal trades around 30.5 times 2025 adjusted EPS and offers an owner-earnings yield below the French ten-year government-bond yield.
• The €4.247 billion Kering Beauté purchase generated €2.841 billion of provisional goodwill, while acquired earnings and initial return on capital remain undisclosed.
• The Gucci licence does not begin until July 2027 and major new-product economics are unlikely to be visible before 2028.
• Net debt including leases rose to €12.664 billion after Kering Beauté and the incremental Galderma investment, reducing the balance-sheet optionality that historically supported the premium.
• China’s improvement is concentrated in selective categories, while mass demand, travel retail and consumer confidence remain vulnerable.

[Pre-mortem]

The first failure script begins in late 2026. Chinese premium beauty slows after the initial low-base recovery, North Asia adjusted growth returns below zero, and Consumer Products grows only 1–2%. Dermatological Beauty decelerates to 5% as competitors increase pharmacy promotion. Group adjusted growth falls to 3%, operating margin slips from the first-half record of 21.3% to a full-year 19.7%, and adjusted EPS stalls near €13. The market reduces the multiple from 30 times to 21 times. The share price falls toward €270, about 30% below the current price, before dividends.

The more severe script runs through 2028. Gucci’s relaunch is delayed or fails to gain retailer sell-through, Creed’s niche-fragrance growth normalises, and royalties plus launch investment keep Luxe margin near 19–20%. Management records part of the €2.841 billion goodwill as impaired while another acquisition keeps net debt elevated. Group EPS falls to €11–€12 and the multiple compresses to 18 times. A €198–€216 share price would represent a decline of about 44–49%.

[Final research conclusion]

L’Oréal remains one of the strongest operating businesses in global consumer products. The first half of 2026 shows mid-single-digit-plus organic momentum, record margins and unusually favourable growth from high-margin divisions. The evidence supports continued business compounding rather than structural decline. The company is also taking more capital-allocation risk than at any earlier point in its modern history.

The present share price offers limited compensation for a failure of that transition. The base scenario can justify approximately €380–€410 per share, but the conservative value is materially lower and the current cash yield does not exceed the French government-bond yield. Existing long-term holders can reasonably retain exposure while monitoring acquisition returns. A new investor is being asked to pay today for a China recovery and Gucci economics that have not yet been fully established.

The principal concern is structural rather than short-term: organic growth could normalise near the market rate while the Kering assets earn less than L’Oréal’s historic return and the valuation simultaneously moves from premium growth toward consumer staples. A lower purchase price would absorb much of that risk.

【Company-profile scores】

• Fundamental quality: high
• Growth: medium
• Moat: strong
• Financial soundness: strong
• Management credibility: high
• Valuation attractiveness: low
• Risk level: medium
• Suitable investor type: long-term growth

【Investment rating】

• Rating: Hold
• One-line thesis: Record operating quality supports ownership, but a 30-times earnings valuation leaves no margin of safety for acquisition or China disappointment.
• Ideal buy price:

【Ideal Buy Price】250–270 EUR

Basis: about a 20% discount to the midpoint of the €315–€340 conservative fair-value range and an owner-earnings yield of 5% or better.

• Acceptable hold price: €350–€425, corresponding to approximately ±10% around the current €387.50 share price
• Clearly overvalued price: €530–€560, beginning more than 10% above the optimistic fair-value range
• Current-price classification: acceptable hold
• Whether to wait for a better price: yes. A new purchase becomes attractive at €270 or below if adjusted organic growth remains at least 4%, operating margin remains above 20%, and there is no material deterioration in Kering integration. The opportunity cost is missing further upside if China and Gucci exceed the base case before the multiple contracts.
• Target holding horizon: 3–5 years
• Expected annualized return: conservative -2% to 1%; base 4% to 7%; optimistic 9% to 12%, including dividends
• Max-loss risk: approximately 44–49% in the combined scenario of failed Gucci scaling, China relapse, EPS falling to €11–€12 and the earnings multiple compressing to about 18 times
• Reassessment-trigger signals: adjusted like-for-like growth below 4% for two consecutive reporting periods; North Asia adjusted growth below zero for two periods; Dermatological Beauty growth below 6%; full-year operating margin below 19.7%; net debt including leases above twice operating profit; or another acquisition exceeding €2 billion before Kering’s return is quantified

【Valuation Range】

• current: 387.50 EUR (close as of 2026-08-04)
• bear (conservative · ideal buy zone): [250, 270]
• base (fair · acceptable hold zone): [350, 425]
• bull (optimistic · above the clearly-overvalued line): [530, 560]

[Research uncertainties]

The acquired revenue, EBITDA and cash flow attributable specifically to Creed, Bottega Veneta and Balenciaga were not separately disclosed in the H1 accounts. The initial return on the €4.247 billion purchase price therefore cannot be calculated reliably.

Management’s allocation between maintenance and growth capex is not public. The 60–70% maintenance estimate in this report is an analytical assumption; valuation uses all capex to reduce dependence on it.

Chinese market-share statements are based partly on management’s proprietary market estimates. Public data support an improvement in prestige beauty, but do not provide a complete reconciliation of shipments, retailer inventory and consumer sell-through.

The original 1963 listing price, proceeds and valuation were not found in dependable company or exchange archives reviewed for this report. No figure has been inferred.

Forward peer multiples vary substantially across data providers because Estée Lauder and Shiseido have restructuring costs, ADR conventions and different fiscal periods. The horizontal analysis therefore relies more heavily on operating margins, organic growth and business structure than on a single vendor’s peer multiple.

[Principal sources]

Primary research relied on L’Oréal’s H1 2026 results release, half-year financial report and financial statements.

Historical financial analysis relied on L’Oréal’s annual-results releases and universal registration documents from 2019 through 2025.

Acquisition analysis relied on L’Oréal and Kering transaction announcements, the H1 purchase-price allocation and the July 2026 Gucci-licence disclosure.

Ownership and governance analysis relied on L’Oréal’s dated ownership and governance pages, Nestlé’s transaction release and Nestlé’s 2025 financial statements.

Peer analysis relied primarily on the latest company disclosures from Estée Lauder, Beiersdorf, Shiseido and Procter & Gamble.

Market-size assumptions used McKinsey’s June 2026 beauty-industry research. Price, exchange-rate and bond-yield observations were dated to August 4, 2026.

Other tickers mentioned

• EL.US — closest listed pure-play comparison in prestige beauty and Asian travel retail
• BEI.XETRA — skincare and dermatological-beauty peer with NIVEA, Eucerin and Aquaphor
• 4911.TSE — Asian prestige-beauty peer with high China and travel-retail exposure
• PG.US — global consumer-products scale benchmark and mass-beauty competitor
• COTY.US — incumbent Gucci beauty licensee and fragrance-licensing comparison
• PUIG.MC — prestige-fragrance and fashion-licence competitor
• KER.PA — seller of Kering Beauté and long-term licensor of Gucci, Bottega Veneta and Balenciaga
• MC.PA — luxury-group comparison with internally operated perfumes and cosmetics
• NESN.SW — 20.16% strategic shareholder and potential future equity-supply overhang
• GALD.SW — dermatology company in which L’Oréal held a 20% equity-accounted interest at June 30, 2026

This report is based on public information and does not constitute investment advice. Markets carry risk; invest with caution.